The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

A first embodiment of a composition for treating vitiligo includes Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, and Psoralea corylifolia black seed powder. A second embodiment of a composition for treating vitiligo can include Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, Berberries (or Berberis) vulgaris root powder, red clay (with trace copper), and Ptychotis verticillata root powder. Topical administration of the first composition followed by UV radiation exposure can facilitate inducing melanogenesis as well as generating ROS. Topical administration of the second composition following the UV radiation exposure can scavenge the ROS generated by the first composition.

A first embodiment of a composition for treating vitiligo includes Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, and Psoralea corylifolia black seed powder. A second embodiment of a composition for treating vitiligo can include Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, Berberries (or Berberis) vulgaris root powder, red clay (with trace copper), and Ptychotis verticillata root powder. Topical administration of the first composition followed by UV radiation exposure can facilitate inducing melanogenesis as well as generating ROS. Topical administration of the second composition following the UV radiation exposure can scavenge the ROS generated by the first composition.

The present invention is directed to methods for improving muscle and connective tissue with Shilajit, including reducing collagen degradation and reducing the loss of strength due to muscle fatigue. The present methods improve muscle building and repair as well as the health of skin, cartilage, connective tissues, muscle, vascular tissues, bones, and teeth, and treat collagen-related disorders such as arthritis and osteoporosis.

The present invention is directed to methods for improving muscle and connective tissue with Shilajit, including reducing collagen degradation and reducing the loss of strength due to muscle fatigue. The present methods improve muscle building and repair as well as the health of skin, cartilage, connective tissues, muscle, vascular tissues, bones, and teeth, and treat collagen-related disorders such as arthritis and osteoporosis.

Maillard reaction products produced by heating carbohydrates with one or more amino acids (e.g., lysine), at basic pH and for a selected reaction time at a particular concentration in solution, can exhibit inhibitory activity against Aggregatibacter actinomycetemcomitans.

The present invention relates to a monoclonal mouse antibody produced by the hybridoma cell deposited under ICLC accession number ICLC PD no 16001. Furthermore, the invention relates to an antibody comprising a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3, and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences GFTFSSFGMH (SEQ ID NO: 1), YISSGSGNFYYVDTVKG (SEQ ID NO: 43), STYYHGSRGAMDY (SEQ ID NO: 3), SASSSVSSMYWY (SEQ ID NO: 4), DTSKMAS (SEQ ID NO: 5), and QQWSSYPPIT (SEQ ID NO: 6), respectively. In addition, the invention relates to antibodies recognizing the same epitope.

The present invention relates to a monoclonal mouse antibody produced by the hybridoma cell deposited under ICLC accession number ICLC PD no 16001. Furthermore, the invention relates to an antibody comprising a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3, and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences GFTFSSFGMH (SEQ ID NO: 1), YISSGSGNFYYVDTVKG (SEQ ID NO: 43), STYYHGSRGAMDY (SEQ ID NO: 3), SASSSVSSMYWY (SEQ ID NO: 4), DTSKMAS (SEQ ID NO: 5), and QQWSSYPPIT (SEQ ID NO: 6), respectively. In addition, the invention relates to antibodies recognizing the same epitope.

The present disclosure relates generally to methods for treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of hematopoietic cells obtained from a candidate donor having a specific combination of KIR3DL1 and HLA-B alleles. Also disclosed herein are methods for protecting a leukemia patient recipient from leukemic relapse following allogeneic hematopoietic cell transplantation (HCT).